Tags

Type your tag names separated by a space and hit enter

Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults.
Clin Endocrinol (Oxf). 2004 Jul; 61(1):81-7.CE

Abstract

OBJECTIVE

To evaluate circulating levels of ghrelin and adiponectin (ApN) in GH-deficient (GHD) adults before and after short- and long-term recombinant human GH (rhGH) administration.

PATIENTS AND METHODS

Twenty-three patients were studied. Seventeen subjects (Group A, 12 men, five women) were evaluated at baseline and after 1 year rhGH therapy (dose mean +/- SD: 0.3 +/- 0.1 mg/day) with the assessment of serum IGF-I, ghrelin, ApN, leptin, insulin and glucose levels, percentage of body fat (BF%), HOMA-IR and QUICKI. Seventeen age-, sex- and body mass index (BMI)-matched healthy subjects were recruited for comparisons. Six patients (Group B, three men, three women) underwent IGF-I generation test (rhGH 0.025 mg/kg/day for 7 days), blood sampled at baseline and on day 8 for determination of IGF-I, ghrelin and ApN levels.

RESULTS

Group A: at baseline GHD patients showed low IGF-I levels and BF% significantly higher than controls (31.4 +/- 2.5 vs. 26.4 +/- 1.3, P < 0.05). Glucose, insulin, leptin, tryglicerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels, as well as HOMA-IR and QUICKI values were similar in the two series, while total cholesterol levels were higher in GHD. In GHD, ghrelin levels were significantly lower than in controls (193.9 +/- 27.1 vs. 298.1 +/- 32.5 pmol/l, respectively, P = 0.02), while ApN levels were similar (10.2 +/- 1.1 and 9 +/- 1 mg/l, respectively, P = ns). After 1 year of rhGH therapy, BF%, BMI, serum total and LDL cholesterol significantly decreased, serum leptin levels showed a trend to decrease, while HOMA-IR and QUICKI did not change. Ghrelin and ApN levels significantly increased from 193.9 +/- 27.1 to 232.4 +/- 26.3 pmol/l (P < 0.01) and from 8.6 +/- 0.8 to 10.3 +/- 1.1 mg/l (P < 0.05), respectively. In group B, the expected increase in IGF-I levels was associated with a significant decrease in ghrelin levels, while ApN did not change.

CONCLUSION

GHD patients showed serum ghrelin lower than controls, probably due to the higher BF%. No difference in ApN was observed. Ghrelin and ApN increments induced by long-term treatment may be related to the significant BMI and BF% reduction that is the predominant metabolic effect of rhGH therapy. Conversely, the decrease in ghrelin levels observed after short-term rhGH administration may be consistent with an inhibitory feedback of GH and/or IGF-I on ghrelin release.

Authors+Show Affiliations

Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15212648

Citation

Giavoli, Claudia, et al. "Different Effects of Short- and Long-term Recombinant hGH Administration On Ghrelin and Adiponectin Levels in GH-deficient Adults." Clinical Endocrinology, vol. 61, no. 1, 2004, pp. 81-7.
Giavoli C, Cappiello V, Corbetta S, et al. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol (Oxf). 2004;61(1):81-7.
Giavoli, C., Cappiello, V., Corbetta, S., Ronchi, C. L., Morpurgo, P. S., Ferrante, E., Beck-Peccoz, P., & Spada, A. (2004). Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clinical Endocrinology, 61(1), 81-7.
Giavoli C, et al. Different Effects of Short- and Long-term Recombinant hGH Administration On Ghrelin and Adiponectin Levels in GH-deficient Adults. Clin Endocrinol (Oxf). 2004;61(1):81-7. PubMed PMID: 15212648.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. AU - Giavoli,Claudia, AU - Cappiello,Vincenzo, AU - Corbetta,Sabrina, AU - Ronchi,Cristina L, AU - Morpurgo,Paola S, AU - Ferrante,Emanuele, AU - Beck-Peccoz,Paolo, AU - Spada,Anna, PY - 2004/6/24/pubmed PY - 2004/9/28/medline PY - 2004/6/24/entrez SP - 81 EP - 7 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 61 IS - 1 N2 - OBJECTIVE: To evaluate circulating levels of ghrelin and adiponectin (ApN) in GH-deficient (GHD) adults before and after short- and long-term recombinant human GH (rhGH) administration. PATIENTS AND METHODS: Twenty-three patients were studied. Seventeen subjects (Group A, 12 men, five women) were evaluated at baseline and after 1 year rhGH therapy (dose mean +/- SD: 0.3 +/- 0.1 mg/day) with the assessment of serum IGF-I, ghrelin, ApN, leptin, insulin and glucose levels, percentage of body fat (BF%), HOMA-IR and QUICKI. Seventeen age-, sex- and body mass index (BMI)-matched healthy subjects were recruited for comparisons. Six patients (Group B, three men, three women) underwent IGF-I generation test (rhGH 0.025 mg/kg/day for 7 days), blood sampled at baseline and on day 8 for determination of IGF-I, ghrelin and ApN levels. RESULTS: Group A: at baseline GHD patients showed low IGF-I levels and BF% significantly higher than controls (31.4 +/- 2.5 vs. 26.4 +/- 1.3, P < 0.05). Glucose, insulin, leptin, tryglicerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels, as well as HOMA-IR and QUICKI values were similar in the two series, while total cholesterol levels were higher in GHD. In GHD, ghrelin levels were significantly lower than in controls (193.9 +/- 27.1 vs. 298.1 +/- 32.5 pmol/l, respectively, P = 0.02), while ApN levels were similar (10.2 +/- 1.1 and 9 +/- 1 mg/l, respectively, P = ns). After 1 year of rhGH therapy, BF%, BMI, serum total and LDL cholesterol significantly decreased, serum leptin levels showed a trend to decrease, while HOMA-IR and QUICKI did not change. Ghrelin and ApN levels significantly increased from 193.9 +/- 27.1 to 232.4 +/- 26.3 pmol/l (P < 0.01) and from 8.6 +/- 0.8 to 10.3 +/- 1.1 mg/l (P < 0.05), respectively. In group B, the expected increase in IGF-I levels was associated with a significant decrease in ghrelin levels, while ApN did not change. CONCLUSION: GHD patients showed serum ghrelin lower than controls, probably due to the higher BF%. No difference in ApN was observed. Ghrelin and ApN increments induced by long-term treatment may be related to the significant BMI and BF% reduction that is the predominant metabolic effect of rhGH therapy. Conversely, the decrease in ghrelin levels observed after short-term rhGH administration may be consistent with an inhibitory feedback of GH and/or IGF-I on ghrelin release. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/15212648/Different_effects_of_short__and_long_term_recombinant_hGH_administration_on_ghrelin_and_adiponectin_levels_in_GH_deficient_adults_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0300-0664&amp;date=2004&amp;volume=61&amp;issue=1&amp;spage=81 DB - PRIME DP - Unbound Medicine ER -